secwatch / observer
8-K filed November 19, 2024, 6:59 PM ET ticker CDT CIK 0001896212
leadership confidence high sentiment neutral materiality 0.45

Conduit Pharma appoints director Fry (420K options); amends CFO pay (£400K, 40% bonus) and quorum rule

CDT Equity Inc.

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001493152-24-046849
form_type
8-K
ticker
CDT
cik
0001896212
company_name
CDT Equity Inc.
filed_at
2024-11-19T23:59:59+00:00
discovered_at
2026-05-14T18:03:10.292024+00:00
generated_at
2026-05-29T22:41:31.066582+00:00
sec_items
["5.02", "5.03", "9.01"]
event_type
leadership
sentiment
neutral
materiality_score
0.45
calibrated_materiality_score
0.45
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001493152-24-046849
json_url
https://secwatch.observer/filing/0001493152-24-046849.json
markdown_url
https://secwatch.observer/filing/0001493152-24-046849.md
text_url
https://secwatch.observer/filing/0001493152-24-046849.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1896212/000149315224046849/0001493152-24-046849-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1896212/000149315224046849/form8-k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Simon Fry

director
CDT · CDT Equity Inc.
Effective
2024-12-18
Filed
November 19, 2024, 6:59 PM ET
the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024

Source-grounded claims

9f4142d9a2

Simon Fry was appointed as director at CDT Equity Inc..

the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

Comparable filings

FIBK

First Interstate BancSystem: three directors retire per age policy; charter amended to plurality voting

FIRST INTERSTATE BANCSYSTEM INC May 29, 2026, 4:26 PM ET leadership Items 5.02, 5.03, 5.07, 9.01

same fact type: executive_change same SEC item: 5.02, 5.03, 9.01 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024

Comparable filing

on May 27, 2026, each of Ms. Patricia L. Moss and Messrs. David L. Jahnke and Stephen M. Lacy, each having reached the retirement age of 72, was deemed to have retired and resigned automatically from the Company’s Board of Directors

Filing page SEC filing

TKNO

Alpha Teknova director Irene Davis to retire; board reduced from 8 to 7; shareholder votes approved nominees and auditor

Alpha Teknova, Inc. June 1, 2026, 5:22 PM ET leadership Items 5.02, 5.07, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024

Comparable filing

On May 27, 2026, Irene Davis, a member of the Board of Directors (the “Board”) of Alpha Teknova, Inc. (the “Company”) and a member of the Nominating and Corporate Governance Committee, notified the Company of her intention not to stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “Meeting”) and to retire from the Board and all committees thereof, effective upon the date of the Meeting.

Filing page SEC filing

WTTR

Select Water Solutions COO Skarke moves to Chief Commercial Officer; no successor named

Select Water Solutions, Inc. June 1, 2026, 5:00 PM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024

Comparable filing

Effective June 1, 2026, Michael C. Skarke transitioned from serving as the Executive Vice President and Chief Operating Officer of Select Water Solutions, Inc. (the “Company”) to serving as the Company’s Executive Vice President and Chief Commercial Officer,

Filing page SEC filing

JOB

Darla Moore resigns from GEE Group board effective June 1, 2026, due to other commitments

GEE Group Inc. June 1, 2026, 4:47 PM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024

Comparable filing

On June 1, 2026, GEE Group Inc. (the “Company”) (NYSE American: JOB) issued a press release announcing that Ms. Darla Moore, has resigned as a member of the Board of Directors (the “Board”) and from all committees of the Company’s Board effective June 1, 2026, due to the time requirements necessary for her existing and new business commitments.

Filing page SEC filing

LPX

LP Building Solutions announces CFO succession: Alan Haughie to retire; Aaron Howald named CFO effective Sept 1, 2026

LOUISIANA-PACIFIC CORP June 1, 2026, 4:31 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024

Comparable filing

On May 27, 2026, Alan J.M. Haughie, Executive Vice President and Chief Financial Officer of Louisiana-Pacific Corporation (“LP”, the “Company”), notified the Board of Directors of LP (the “Board”) of his intention to retire from the role of Executive Vice President and Chief Financial Officer, effective September 1, 2026.

Filing page SEC filing

LOGC

ContextLogic appoints Scott Stewart as CFO & COO effective June 1; interim CFO resigns

ContextLogic Holdings Inc. June 1, 2026, 4:15 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024

Comparable filing

On June 1, 2026 the Company also announced the appointment of Scott Stewart, age 53, as Chief Financial Officer and Chief Operating Officer, effective June 1, 2026 (the “Effective Date”).

Filing page SEC filing

VMI

Former CFO Thomas Liguori enters separation agreement; $4.9M retirement benefits

VALMONT INDUSTRIES INC June 1, 2026, 4:15 PM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024

Comparable filing

Valmont Industries Inc. previously reported the appointment of John Schwietz as Valmont’s Executive Vice President and Chief Financial Officer and Corporate Secretary, effective April 8, 2026, to succeed Thomas Liguori.

Filing page SEC filing

PSQH

PSQ Holdings SVP of People Michael Hebert resigns; severance of $137,500

PSQ Holdings, Inc. June 1, 2026, 4:02 PM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024

Comparable filing

On May 26, 2026, Michael Hebert resigned from his position of Senior Vice President of People of PSQ Holdings, Inc. (the “Company”), effective May 31, 2026.

Filing page SEC filing

Source: SEC EDGAR
accession 0001493152-24-046849

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.